Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.20.2
ACCRUED EXPENSES
 6 Months Ended
Jun. 30, 2020
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

 

8. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    June 30,
2020		     December 31,
2019		  
             
Accrued clinical operations and trials costs   $ 16,901,307     $ 14,242,669  
Accrued product development costs     5,695,552       3,573,231  
Accrued compensation     3,842,249       3,673,111  
Accrued other     1,705,036       958,928  
Total   $ 28,144,144     $ 22,447,939